Work

Abstract 3674: Pharmacodynamic assessment in whole blood for the BET bromodomain inhibitor CPI-0610 of target engagement in patients with progressive lymphoma

Year: 2018

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2018-3674

Authors: Jennifer A. Mertz, Kristie A. Blum, Anas Younes, Jeremy S. Abramson, Michael B. Maris, Ian W. Flinn, Andre Goy, Darrell R. Borger, Michael R. Cooper, Robert J. Sims

Institutions: Constellation Pharmaceuticals (United States), The Ohio State University, Memorial Sloan Kettering Cancer Center, Massachusetts General Hospital, Colorado Blood Cancer Institute, Sarah Cannon, Hackensack University Medical Center

Language: English

Topic: Protein Degradation and Inhibitors

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2886325228

Cites:

Cited by: 2

Related to: 10